<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580745</url>
  </required_header>
  <id_info>
    <org_study_id>MORF-057-101</org_study_id>
    <nct_id>NCT04580745</nct_id>
  </id_info>
  <brief_title>Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers</brief_title>
  <official_title>A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morphic Therapeutic, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Morphic Therapeutic, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple&#xD;
      ascending doses of MORF-057 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Actual">April 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and safety signals observed during single and multiple ascending doses of MORF-057 administered orally to healthy adult subjects</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Subject incidence of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MORF-057 in a fed state</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Cmax (Food Effect cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax (Tmax) of MORF-057 in a fed state</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Tmax (Food Effect cohort)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) during single and multiple ascending doses of MORF-057</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Cmax of MORF-057</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax) during single and multiple ascending doses of MORF-057</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Tmax of MORF-057</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and safety signals observed during single dose of MORF-057 administered after a meal to healthy subjects.</measure>
    <time_frame>Day -1 to Day 28</time_frame>
    <description>Subject incidence of adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MORF-057</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.&#xD;
Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.&#xD;
MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MORF-057</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.&#xD;
MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORF-057</intervention_name>
    <description>SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.&#xD;
Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.&#xD;
MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.</description>
    <arm_group_label>MORF-057</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MORF-057</intervention_name>
    <description>SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.&#xD;
MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.</description>
    <arm_group_label>Placebo for MORF-057</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 to 65 years old with a body mass index&#xD;
             between 18 and 32 kg/m2&#xD;
&#xD;
          -  Determined to be medically healthy by the Investigator.&#xD;
&#xD;
          -  Use of acceptable methods of contraceptives.&#xD;
&#xD;
          -  Ability to provide written informed consent and to understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any malignancy, except basal or squamous cell carcinoma of the skin that&#xD;
             resolved or in remission prior to Screening.&#xD;
&#xD;
          -  Abnormal laboratory values at Screening.&#xD;
&#xD;
          -  Any clinically significant major diseases.&#xD;
&#xD;
          -  Female who is pregnant or breastfeeding, or planning to become pregnant during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Unwilling or unable to comply with the requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medpace</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MORF-057</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

